BioSpace News Archive

The U.S. Food and Drug Administration announced the following actions taken in its ongoing response effort to the COVID-19 pandemic

As a response to the COVID-19 crisis, the National Spine Health Foundation has launched a collection of resources offering guidance for those quarantined to their homes at this time

Extremity Medical, a global medical device company with expertise in innovative implants for upper and lower extremities, announced it has received FDA 510(k) clearance for the first total wrist replacement implant designed to emulate natural wrist range of motion in patients with wrist arthritis and other degenerative wrist conditions.

MetroPlus Health Plan today announced a new program to offer telehealth medical and mental health provider visits to its membership.

Scientists at Texas Biomedical Research Institute (Texas Biomed) today announced the launch of a comprehensive research initiative to investigate multiple animal species and their response to the novel coronavirus disease (COVID-19).

Same-Day, Immediate Orthopaedic Care Helps Patients Avoid Crowds, Wait Times and Exposure in the ER or Urgent Care

Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced positive preliminary results from a Phase 1a/1b clinical trial (AB-729-001) in healthy subjects and two cohorts of chronic hepatitis B subjects on nucleos(t)ide antiviral therapy, all of whom received a single subcutaneous injection of AB-729.

electroCore, Inc. announced the appointments of three new independent members to its Board of Directors effective April 2, 2020.

Hemodialysis patients treated with Optiflux® high flux single-use dialyzers experienced a mean increase in serum albumin levels, according to results from a recent clinical trial and separate retrospective analysis conducted by Fresenius Medical Care North America.

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on recent developments.